Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Synlogic Collaborates with Roche to Evaluate the Combination of SYNB1891 and Tecentriq (atezolizumab) for Advanced Solid Tumors

Shots:                                                                                                                                               

  • Roche & Synlogic enter into a clinical collaboration to evaluate the combination therapy of Synlogic’s SYNB1891 with Roche’s Tecentriq (atezolizumab) to treat patients with advanced solid tumors
  • Synlogic plans to file an IND for SYNB1891 to the US FDA in H2’19 for the onset of P-I clinical studies evaluating SYNB1891 as monothx. and in combination with Tecentriq (atezolizumab)
  • SYNB1891 (administered intratumorally) is a non-pathogenic strain of E.coli, engineered to express a STING agonist & stimulating the innate immune system. Synlogic also developing it as a Synthetic Biotic therapy designed to act locally & providing a systemic effect in patients

Click here to read full press release/ article | Ref: Synlogic | Image: Synlogic